Take­da eyes path­way to nat­ur­al killer ther­a­pies, tee­ing up $100M to part­ner with KSQ for its CRISPR-screened mol­e­cules

The po­ten­tial ap­pli­ca­tions for CRISPR/Cas9 con­tin­ue to grow as drug­mak­ers look for nov­el ways to use the pow­er­ful gene edit­ing plat­form to re­work drug dis­cov­ery …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER